Brought to you by 
Celltrion, Hospira to co-market biogenerics; certain rights later returned to Celltrion
02 Nov 2015
Executive Summary
Celltrion Inc. (biosimilars of blockbuster biologics), its Celltrion Healthcare division, and Hospira Inc. (specialty generic injectables) will collaborate on the manufacturing and supply of eight biogeneric products that are currently under development by Celltrion.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celltrion, Hospira to co-market biogenerics; certain rights later returned to Celltrion
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice